ATNX

Oraxol

Angiosarcoma

Stage (next event)

Expected Date

Phase 2

TBD

Catalyst Info & Data Links

TITLE: Oraxol for Angiosarcoma Phase 2 Readout

  • NCT03544567: A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2 Readout 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • Paclitaxel is a widely used IV administered tubulin-stabilizing chemotherapeutic agent. By administering paclitaxel orally with encequidar, we have been able to achieve similar paclitaxel exposures compared to the widely used 80 mg/m² IV weekly dosing regimen.

  • Current clinical data suggests the potential of a better clinical response and tolerability profile, which can likely be attributed to the better pharmacokinetic profile achieved. Additionally, oral paclitaxel and encequidar may offer patients with paclitaxel-responsive tumors freedom from the burden of infusion clinic visits, premedication, and potentially dangerous infusion-related hypersensitivity-type reactions. Oral paclitaxel and encequidar has completed a Phase 3 pivotal trial in metastatic breast cancer, with several additional on-going clinical studies as monotherapy and in combination with other proven anticancer agents.

  • Read more here

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon